The FDA approval of denileukin diftitox (Lymphir) marked a significant shift in this paradigm. As a first-in-class immunotoxin, it employs a dual-action mechanism: directly targeting interleukin-2 (IL ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

A BRAVE cancer fighter who is currently in remission after his third bout of the disease is undergoing gruelling treatment ahead of a donor ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...

Following the FDA approval of rilzabrutinib (Wayrilz; Sanofi) for immune thrombocytopenia (ITP), a rare autoimmune disorder, David Kuter, MD, DPhil, highlights the most pressing a ...

Pharmaceutical and biotechnology companies are intensifying their focus on research areas to address the unmet needs of highly effective treatments for folliculotropic mycosis fungoides. Concurrently, ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the co ...

Allie Reece has shared her cancer journey on TikTok, where she has built a supportive community of thousands of followers ...

After a sluggish first half, the drug and biotech sector has staged a recovery over the past two to three months. This ...

The global cancer drugs market is surging toward $594.3 billion by 2035 as high-tech immunotherapies begin to replace ...

UW researchers found potential new treatments for a rare pediatric brain cancer each year that has a median survival time of ...

The publisher, famed for its ‘Best and Worst Diets’ rankings, turned its attention to trends shaping our health. Learn which ...